The breed, prized for profitability and an ability to adapt to climate change, garners celebrity status in the Central Asian country
asia2 hours ago
Gulf Pharmaceutical Industries (Julphar) has announced the signing of an exclusive license and production agreement with Quantum Genomics, a leading biopharmaceutical company specializing in the development of first-in-class cardiovascular drugs, to market and produce firibastat in the Middle East, all African countries, CIS and Turkey.
The new partnership comes in line with Julphar vision to form robust strategic alliances on the global level, that will help enhance patients’ access to innovative healthcare solutions. The launch of firibastat will address the unmet medical need of up to 25 per cent of all hypertension patients who currently show resistance or are difficult to treat with available therapy alternatives.
Julphar will be Quantum Genomics’ exclusive production partner and will receive exclusive rights to market firibastat in the following geographic areas: the Middle East North Africa region, CIS, Turkey and all other countries on the African continent.
In addition, Julphar will become the preferred manufacturing partner of firibastat for Quantum Genomics in other parts of the world. This new landmark reflects Julphar’s commitment to establishing innovative biopharmaceutical solutions to enhance the UAE’s competitiveness in this strategic sector.
Dr. Essam Mohammed, Julphar’s CEO, said: “Julphar is delighted to partner with Quantum Genomics to commercialize firibastat, the first in class molecule to treat resistant and difficult-to-treat hypertension, and to produce it in our state-of-the-art manufacturing facilities in Ras Al Khaimah. We are confident that firibastat will add a strong value to the treatment of this unmet medical need and to Julphar’s portfolio.”
“The new landmark agreement brings together a stronger focus on innovative ways to address critical diseases in the MENA region through manufacturing high-quality medications locally,” he added.
Jean-Philippe Milon, CEO of Quantum Genomics, said: "Julphar, which was founded forty years ago, is one of the largest pharmaceutical companies in the Mena region. Its success has been built on its comprehensive portfolio including anti-infectives, dermatology, and diabetes products, and its presence in all key MENA markets. Its business is expanding fast and cardiology is one of the key areas of investment. Julphar is also amongst the region’s largest producers and is the ideal partner to support firibastat’s future production needs. We’re already exploring how Julphar could meet some of those requirements for the United States and Europe.”
business@khaleejtimes.com
The breed, prized for profitability and an ability to adapt to climate change, garners celebrity status in the Central Asian country
asia2 hours ago
Thousands of schools have suspended classes due to the heat, affecting more than 3.6 million students, education ministry data shows
asia2 hours ago
Despite the growing market share of domestic automakers, Teslas remain among the best-selling EVs in the Asian country
auto2 hours ago
The entire plan will see cow-breeding and poultry projects come up near the massive wheat farm and the dairy farm will form the third phase
uae2 hours ago
Modi, 73, remains resoundingly popular after a decade in office, and he is widely expected to win a third term
asia2 hours ago
With over seven years of experience in branding and social media, and three years in motion graphics and editing, Arkan's expertise spans a wide range of creative domains
kt network3 hours ago
Names of leading brands in various sectors revealed in a new report by Brand Finance
uae3 hours ago
Four workers died when the drone struck a condensate storage tank at Khor Mor Complex, Dana Gas said in a statement to the ADX
mena4 hours ago